Hogg JA. Steroids, the steroid community, and Upjohn in perspective: a profile of innovation. Steroids. 1002;57:593–616.
Mahaguna V, McDermott JM, Zhang F, Ochoa F. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm. 2004;30(10):1069–78.
Food and Drug Administration. Available via the internet at http://www.cfsan.fda.gov/~dms/cfsand04.html. Accessed 19 Sep 2006.
Women’s International Pharmacy. Especially Designed for Women. Youngtown, Ariz, and Madison, Wisc., USA: Women’s International Pharmacy; 8–9 April 2002.
Premier Pharmacy. Available at http://premier-pharmacy.com/abouthrt3.html. Accessed Jul 2005. (PDF no longer available)
MedXLife. Available at http://medxlife.com/getArticles.asp?aId=54&categoryId=10. Accessed 5 Nov 2004.
College Pharmacy. Available at http://www.collegepharmacy.com/specializations/biest.asp. Accessed Jul 2005.
Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause. 2003;10(1):13–8.
Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol. 1999;94:225–8.
Lee J. Natural Progesterone: The Multiple Roles of a Remarkable Hormone. Sebastopol, Calif: BLL Publishing; 1993.
Lee JR, Zava D, Hopkins V. What Your Doctor May Not Tell You About Breast Cancer! How Hormone Balance Can Help Save Your Life. New York, NY: Warner Books; 2002.
Lee JR, Hanley J, Hopkins V. What Your Doctor May Not Tell You About Premenopause: Balance Your Hormones and Your Life from Thirty to Fifty. New York, NY: Warner Books; 1999.
Lee JR, Hopkins V. What Your Doctor May Not Tell You About Menopause: The Breakthrough Book on Natural Progesterone. New York, NY: Warner Books; 2004.
AltMedNetwork. Available at http://www.altmednetwork.net/whealth/progest_crm.html. Accessed Jun 2005.
Pure Essence Labs. Available at http://www.pureessencelabs.com/pdf/femcreme.pdf. Accessed Jun 2005. (PDF no longer available)
Sommers S. Ageless: the naked truth about bioidentical hormones. New York, NY: Crown Publishers; 2006:7, 23, 71.0.
DrErika.com. Available at http://drerika.com/EN/index.html. Accessed 31 Oct 2005.
Hotze S. Hormones and the woman’s life cycles. Available at http://www.drhotze.com/EN/online_articles/389.html. Accessed Feb 2007
Adams C, Cannell S. Women’s beliefs about “natural” hormones and natural hormone replacement therapy. Menopause. 2001;8(6):433–40.
Writing group for the Women’s Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
Anderson GL, Limacher M, Assaf AR, et al., Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.
Cherry N, Gilmour K, Hannaford P, et al., ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002;360(9350):2001–8.
ESPRIT. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet. 2002;360:2001–8.
Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al.,WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation. 2006;113(20):2425–34.
Wassertheil-Smoller S, Hendrix SL, Limacher M, et al., WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA. 2003;289(20):2673–84.
Shumaker SA, Legault C, Rapp SR, et al., WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651–62.
Shumaker SA, Legault C, Kuller L, et al., Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291(24):2947–58.
Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935–48.
Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348(19):1839–54.
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345(17):1243–9.
Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol Suppl (Copenh). 1980;233:17–27.
Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606–16.
Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer. 2004;90(1):153–9.
Manjer J, Johansson R, Berglund G, et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control. 2003;14(7):599–607.
Key TJ, Appleby PN, Reeves GK, et al., Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218–26.
Onland-Moret NC, Kaaks R, van Noord PA, et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer. 2003;88(9):1394–9.
Yu H, Shu XO, Shi R, et al. Plasma sex steroid hormones and breast cancer risk in Chinese women. Int J Cancer. 2003;105(1):92–7.
Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292–1299.
Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci. 2003;72(8):877–83.
Mady EA, Ramadan EE, Ossman AA. Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers. 2000;16(3–4):151–7.
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448–54.
Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. Gynecol Endocrinol. 2005;21(2):101–5.
Wren, B. G., McFarland, K., Edwards, L. Micronised transdermal progesterone and endometrial response. Lancet 1999;354:1447–8.
Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril. 2003;79(1):221–2 (Jan).
Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas. 2002;41:1–6.
Carey BJ, Carey AH, Patel S, Carter G, Studd JW. A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women. BJOG. 2000;107(6):722–6.
O’Leary PO, Feddema P, Chan K, et al. Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women. Clin Endocrinol. 2000;53:615–20.
Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol. 1999;180(6 Pt 1):1504–11.
Cooper A, Spencer C, Whitehead MI, Ross D, Barnard GJ, Collins WP. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet. 1998;351(9111):1255–6.
Hermann AC, Nafziger AN, Victory J, Kulaway R, Rocci ML, Bertino JS. Over-the-counter progesterone cream produces significant drug exposure compared to a Food and Drug Administration approved oral progesterone. J Clin Pharmacol. 2005;45:614–9.
Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause. 2004;11(3):356–67.
van Haaften M, Donker GH, Sie-Go DM, Haspels AA, Thijssen JH. Biochemical and histological effects of vaginal estriol and estradiol applications on the endometrium, myometrium and vagina of postmenopausal women. Gynecol Endocrinol. 1997;11(3):175–85.
Granberg S, Ylostalo P, Wikland M, Karlsson B. Endometrial sonography and histological findings in women with and without hormonal replacement therapy suffering from post menopausal bleeding. Maturitas. 1997;27:35–40.
Weiderpass E, Baron JA, Adami H-O, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet. 1999;353:1824–8.
Granberg S, et al. The effects of oral estriol on the endometrium in postmenopausaul women. Maturitas. 2002;42:149–56.
Scialli A, Fugh-Berman A. The effects of oral estriol on the endometrium in postmenopausal women. Maturitas. 2003;45(2):147; author reply 149.
Food and Drug Administration. Food and Drug Administration Labeling Guidance for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms—Prescribing Information for Health Care Providers and Patient Labeling, revision 1. USA: Center for Drug Evaluation and Research (CDER), revision 1. Available at http://www.fda.gov/cder/guidance/index.htm; February 2004.
Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause. 2005;12(2):232–7.
Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. BJOG. 2005;112(10):1402–6.